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Abstract
One of the promising frontiers of bioengineering is the controlled release of a therapeutic drug from a
vehicle across the skin (transdermal drug delivery). In order to study the complete process, a two-phase
mathematical model describing the dynamics of a substance between two coupled media of different
properties and dimensions is presented. A system of partial differential equations describes the diffu-
sion and the binding/unbinding processes in both layers. Additional flux continuity at the interface and
clearance conditions into systemic circulation are imposed. An eigenvalue problem with discontinuous
coefficients is solved and an analytical solution is given in the form of an infinite series expansion. The
model points out the role of the diffusion and reaction parameters, which control the complex transfer
mechanism and the drug kinetics across the two layers. Drug masses are given and their dependence on
the physical parameters is discussed.
Keywords: Diffusion-reaction equation, transdermal drug delivery, percutaneous absorption, binding –
unbinding, local mass non-equilibrium.
1 Introduction
Transdermal drug delivery (TDD for short) is an approach used to deliver drugs through the skin for thera-
peutic purposes as an alternative to oral, intravascular, subcutaneous and transmucosal routes. Various TDD
technologies are possible including the use of suitable drug formulations, carriers such as nanoparticles
∗Corresponding author.
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and penetration enhancers to facilitate drug delivery and transcutaneous absorption1 . TDD offers several
advantages compared to other traditional delivery methods: controlled release rate, noninvasive adminis-
tration, less frequent dosing, and simple application without professional medical aids, improving patient
compliance. For these reasons it represents a valuable and attractive alternative to oral administration [1].
Drugs can be delivered across the skin to have an effect on the tissues adjacent to the site of application
(topical delivery) or to be effective after distribution through the circulatory system (systemic delivery).
While there are many advantages to TDD, the skin’s barrier properties provide a significant challenge. To
this aim, it is important to understand the mechanism of drug permeation from the delivery device (or
vehicle, typically a transdermal patch or medicated plaster, fig. 1) across the skin [2]. In TDD, the drug
should be absorbed to an adequate extent and rate in order to achieve and maintain uniform, systemic,
effective levels throughout the duration of use. TDD must be carefully tailored to achieve the optimal
therapeutic effect and to deliver the correct dose in the required time [3]. The pharmacological effects
of the drug, tissue accumulation, duration and distribution could potentially have an effect on its efficacy
and a delicate balance between an adequate amount of drug delivered over an extended period of time and
the minimal local toxicity should be found [4]. Most drugs do not penetrate skin at rates sufficient for
therapeutic efficacy and this restrictive nature limits the use of the transdermal route to molecules of low
molecular weight and with moderate lipophilicity. In general, the first skin layer, the stratum corneum,
presents most of the resistance to diffusive transport into skin. Thus, once the drug molecules cross it,
transfer into deeper dermal layers and systemic uptake occurs in a relatively short time. In order to speed
up transdermal permeation of drugs in the stratum corneum, new delivery techniques are currently under
investigation, for example the use of chemical enhancers or microneedles and techniques such as ultrasound,
electroporation and iontophoresis [3, 5].
Mathematical modelling for TDD constitutes a powerful predictive tool for the fundamental understand-
ing of biotransport processes, and for screening processes and stability assessment of new formulations. In
the absence of experiments, a number of mathematical models and numerical simulations have been carried
out regarding TDD, its efficacy and the optimal design of devices [6, 7, 8, 9]. Recent extensive reviews deal
with various aspects of transdermal delivery at different scales [2, 10, 11, 12]. In general, drug absorption
into the skin occurs by passive diffusion and most of the proposed models consider this effect only. On the
other hand, there is a limited effort to explain the drug delivery mechanism from the vehicle platform. This
is a very important issue indeed, since the polymer matrix acts as a drug reservoir, and an optimal design of
its microstructural characteristics would improve the release performances [13]. For example, in the vehicle,
the dissolution of the drug from encapsulated to free phase occurs at a given reaction rate. Another relevant
feature in TDD is the similar binding/unbinding process through the receptor sites in the skin. These drug
association-dissociaton aspects are often neglected or underestimated by most authors who consider purely
diffusive systems in the skin or in the vehicle [20, 21]. One exception is the work of Anissimov et al.[2, 4],
where a linear reversible binding is considered, but the vehicle is taken into account only through a boundary
condition of the first kind. However, it is worth emphasizing that the drug elution depends on the properties
of the “vehicle-skin” system, taken as a whole, and modelled as a coupled two-layered system.
The method used in the present study follows the mathematical approach developed in a series of pre-
viously published papers which successfully describe drug dynamics form an eluting stent embedded in an
arterial wall [14–17]. In these papers, we proposed a number of models of increasing complexity to explain
the diffusion-advection-reaction release mechanism of a drug from the stent coating to the wall, constituted
of a number of contiguous homogeneous media of different properties and extents. Separation of variables
1The term “drug delivery” refers to the release of drug from a polymeric platform where it is initially contained. The name
“percutaneous absorption” is generally related to the same process viewed from the perspective of the living tissue where the drug
is directed to.
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leads to an eigenvalue problem with discontinuous coefficients and an exact solution is given in terms of
infinite series expansion and is based on a two- or multi-layer diffusion model. In the wake of these papers,
a two-layer two-phase coupled model for TDD has been recently presented and a semi-analytical solution
has been proposed for drug concentration and mass in the vehicle and the skin at various times, for special
values of the parameters [18].
In the present paper we extend the above study and remove some of the simplifying assumptions, ob-
taining a solution in a more general form. Together with diffusive effects, the drug dissolution process in
the polymer constituting the vehicle platform and the reversible drug binding process in the skin are also
addressed. A solution of the Fick-type reaction-diffusion equations (reduced problem) serves as the build-
ing block to construct a space-time dependent solution for the general equations (full problem). A major
issue in modelling TDD is the assessment of the key parameters defining skin permeability, diffusion co-
efficients, drug dissociation and association rates. Lacking experimental data and reliable estimates of the
model parameters, we carry out a systematic sensitivity analysis over a feasible range of parameter values.
The results of the simulations provide valuable insights into local TDD and can be used to assess experi-
mental procedures to evaluate drug efficacy, for an optimal control strategy in the design of technologically
advanced transdermal patches.
2 Formulation of the problem
To model TDD, let us consider a two-layered system composed of: (i) the vehicle (the transdermal patch or
the film of an ointment), and (ii) the skin (the stratum corneum followed by the skin-receptor cells and the
capillary bed) (fig. 2). The drug is stored in the vehicle, a reservoir consisting of a polymeric matrix. This is
enclosed on one side with an impermeable backing and having on the other side an adhesive in contact with
the skin. A rate-controlling membrane protecting the polymer matrix may exist. In this configuration, the
first layer is shaped as a planar slab that is in direct contact with the skin, the second layer. As most of the
mass dynamics occurs along the direction normal to the skin surface, we restrict our study to a simplified
one-dimensional model. In particular, we consider as x-axis the normal to the skin surface and oriented with
the positive direction outwards the skin. Without loss of generality, let x0 = 0 be the vehicle-skin interface
and l0 and l1 the thicknesses of the vehicle and skin layers respectively (fig. 2). The vehicle and the skin are
both treated from a macroscopic perspective so that they are represented as two homogeneous media.
Initially, the drug is encapsulated at maximum concentration within the vehicle in a bound phase (e.g.
nanoparticles or crystalline form) (ce): in a such state, it is unable to be delivered to the tissue. Then, a
fraction of this drug (β0ce) is transferred, through an unbinding process, to an unbound – free, biologically
available – phase (c0), and conversely, a part of the free drug (δ0c0) is transferred by a binding process to
the bound state, in a dynamic equilibrium (fig. 3). Also, at the same time, another fraction of free drug (c1)
begins to diffuse into the adjacent skin (delivery). Similarly, in the skin – the release medium – a part of the
unbound drug (β1c1) is metabolized by the cell receptors and transformed in a bound state (cb) (absorption),
and with the reverse unbinding process (δ1cb) again in a unbound phase. Thus, the drug delivery-absorption
process starts from the vehicle and ends to the skin receptors, with bidirectional phase changes in a cascade
sequence, as schematically represented in fig. 3. Local mass non-equilibrium processes, such as bidirec-
tional drug binding/unbinding phenomena, play a key role in TDD, with characteristic times faster than those
of diffusion. In other cases of drug delivery, such as in eluting stents, a second-order saturable reversible
binding model has been proposed [19]: this comprehensive model includes a number of drug dependent
parameters which are difficult to measure experimentally and, nevertheless, does not necessarily apply to
TDD. Here, a linear relationship is commonly used, as the density of binding sites far exceeds the local free
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drug concentration [2, 4]. In the first layer the process is described by the following equations:
∂ce
∂t
= −β0ce + δ0c0 in (−l0, 0) (2.1)
∂c0
∂t
= D0
∂2c0
∂x2
+ β0ce − δ0c0 in (−l0, 0) (2.2)
where D0 (cm2/s) is the effective diffusion coefficient of the unbound solute, β0 ≥ 0 and δ0 ≥ 0 (s−1)
are the unbinding and binding rate constants in the vehicle, respectively. In detail, the rate of release of
encapsulated drug into its free state is implied by the dissociation rate constant β0, while δ0 provides a
representation of the rate at which the free solute re-associates in the bound state.
Similarly, in the second layer, the drug dynamics is governed by similar reaction-diffusion equations:
∂c1
∂t
= D1
∂2c1
∂x2
− β1c1 + δ1cb in (0, l1) (2.3)
∂cb
∂t
= β1c1 − δ1cb in (0, l1) (2.4)
where D1 is the effective diffusivity of unbound drug, β1 ≥ 0 and δ1 ≥ 0 are the binding and unbinding
rate constants in the skin, respectively, defined similarly as above for the vehicle. They can be evaluated
experimentally as described in [4, 9], sometimes through the equilibrium dissociation constant K = δ1
β1
. The
magnitudes of δ1 and β1 are inversely proportional to the typical times associated with the binding-unbinding
processes. However, these reaction times are not negligible compared with the diffusive characteristic times
(slow binding) [11].
To close the previous bi-layered mass transfer system of eqns. (2.1)–(2.4), a flux continuity condition
has to be assigned at the vehicle-skin interface:
−D0
∂c0
∂x
= −D1
∂c1
∂x
at x = 0 (2.5)
As far as the concentration continuity is concerned, this is not guaranteed because of a different drug
partitioning between vehicle and skin. This is taken into account through an appropriate mass transfer
coefficient Pr [9, 11]. Additionally, a semi-permeable rate-controlling membrane or an adhesive film or a
non-perfect vehicle-skin contact, having 1/Pm as mass resistance, might be present at the interface. Thus, a
jump concentration may occur:
−D1
∂c1
∂x
= P (c0 − c1) at x = 0 (2.6)
with P (cm/s) the overall mass transfer coefficient :
1
P
=
1
Pr
+
1
Pm
Estimation of the partition coefficient or of its derived quantity Pr is a very difficult task. The recent review
of Mitragotri et al. [2] provides an excellent overview of the current methods used for its representation.
The usually met condition c0 ∝ c1 does not apply, in our opinion, to time dependent cases.
No mass flux passes between the vehicle and the external surrounding due to the impermeable backing
and we impose a no-flux condition :
D0
∂c0
∂x
= 0 at x = −l0 (2.7)
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Finally, a boundary condition has to be imposed at the skin-receptor (capillary) boundary. At this point
the elimination of drug by capillary system follows first-order kinetics:
Kclc1 +D1
∂c1
∂x
= 0 at x = l1 (2.8)
where Kcl is the skin-capillary clearance per unit area (cm/s). The initial conditions are:
ce(x, 0) = Ce c0(x, 0) = 0 c1(x, 0) = 0 cb(x, 0) = 0 (2.9)
2.1 Dimensionless equations
All the variables and the parameters are now normalized to get easily computable dimensionless quantities
as follows:
x¯ =
x
l1
t¯ =
D1
(l1)2
t φ =
Pl1
D1
l¯0 =
l0
l1
γ =
D0
D1
c¯i =
ci
Ce
K =
Kcll1
D1
β¯i =
βi(l1)
2
D1
δ¯i =
δi(l1)
2
D1
i = 0, 1
By omitting the bar for simplicity, the mass transfer problem (2.1)–(2.4) can be now written in dimensionless
form as:
∂ce
∂t
= −β0ce + δ0c0 in (−l0, 0) (2.10)
∂c0
∂t
= γ
∂2c0
∂x2
+ β0ce − δ0c0 in (−l0, 0) (2.11)
∂c1
∂t
=
∂2c1
∂x2
− β1c1 + δ1cb in (0, 1) (2.12)
∂cb
∂t
= β1c1 − δ1cb in (0, 1) (2.13)
and the interface and boundary conditions (2.5)–(2.8) read:
∂c0
∂x
= 0 at x = −l0
γ
∂c0
∂x
=
∂c1
∂x
−
∂c1
∂x
= φ(c0 − c1) at x = 0
Kc1 +
∂c1
∂x
= 0 at x = 1 (2.14)
supplemented with the initial condition:
ce(x, 0) = 1 c0(x, 0) = 0 c1(x, 0) = 0 cb(x, 0) = 0 (2.15)
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3 Solving a reduced problem
To solve the above problem, let us consider, preliminarily, the associated system of P.D.E.’s obtained from
(2.11)–(2.12) by setting ce = cb = 0:
∂c˜0
∂t
= γ
∂2c˜0
∂x2
− δ0c˜0 − l0 < x < 0
∂c˜1
∂t
=
∂2c˜1
∂x2
− β1c˜1 0 < x < 1 (3.1)
with the same boundary conditions (2.14) and homogeneous initial conditions. We look for a non trivial
solution by separation of variables:
c˜0(x, t) = X0(x)G0(t) c˜1(x, t) = X1(x)G1(t) (3.2)
After substitution, eqns.(3.1) become:(
dG0
dt
+ δ0G0
)
X0 = γX
′′
0G0 − l0 < x < 0(
dG1
dt
+ β1G1
)
X1 = X
′′
1G1 0 < x < 1 (3.3)
From the previous, X0 and X1 must satisfy the spatial eigenvalue problem:
X ′′0 = −λ
2
0X0 − l0 < x < 0
X ′′1 = −λ
2
1X1 0 < x < 1 (3.4)
with:
X ′0 = 0 at x = −l0
γX ′0 = X
′
1 −X
′
1 = φ(X0 −X1) at x = 0
KX1 +X
′
1 = 0 at x = 1 (3.5)
The eigenfunctions of the problem (3.4) are searched as:
X0(x) = a0 cos(λ0x) + b0 sin(λ0x) X1(x) = a1 cos(λ1x) + b1 sin(λ1x) (3.6)
By enforcing the conditions (3.5), we get the following linear system of equations:

a0 sin(λ0l0) + b0 cos(λ0l0) = 0
γλ0b0 = λ1b1
φ(a0 − a1) + λ1b1 = 0
[K cos(λ1)− λ1 sin(λ1)] a1 + [K sin(λ1) + λ1 cos(λ1)] b1 = 0
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A non trivial solution (a0, b0, a1, b1) with:
a0 = a1 −
λ1
φ
b1 = −b0 cot(λ0l0)
b0 =
λ1
γλ0
b1
a1 =
K tan λ1 + λ1
λ1 tan λ1 −K
b1 (3.7)
and b1 arbitrary, exists only if the determinant of the coefficient matrix is zero, i.e.:
λ1 (λ1 tan(λ1)−K) [γλ0 tan(λ0l0)− φ]− γφλ0 tan(λ0l0) (K tan(λ1) + λ1) = 0 (3.8)
In general, the transcendental eqn (3.8) admits infinite eigenvalues. On the other hand, from (3.3), we have:
dG0
dt
+ (δ0 + γλ
2
0)G0 = 0
dG1
dt
+ (β1 + λ
2
1)G1 = 0 (3.9)
In order to satisfy the matching conditions at the interface x = 0 for all t > 0, from (3.9) it follows:
G(t) ≡ G0(t) = G1(t) = exp(−ωt)
with
ω ≡ δ0 + γλ
2
0 = β1 + λ
2
1 (3.10)
From the latter, it follows:
λ0 =
√
λ2
1
+ β1 − δ0
γ
(3.11)
and replacing in (3.8) we get a set of eigenvalues (λk
0
, λk
1
) and of eigenvectors (Xk
0
,Xk
1
) as in eqn. (3.6).
Note that, although from eqn. (3.11) some eigenvalues can be imaginary, this circumstance is excluded with
the numerical values used (see sect. 5). We can easily prove that (Xk
0
,Xk
1
) form a orthogonal system, that
is:
0∫
−l0
Xk0X
q
0
dx+
1∫
0
Xk1X
q
1
dx =
{
0 for k 6= q
Nk for k = q
(3.12)
where
Nk =
1
2
[(
(ak0)
2 + (bk0)
2
)
l0 −
ak
0
bk
0
λk
0
+ (ak1)
2 + 1 +
ak
1
λk
1
]
(3.13)
Finally the concentrations are expressed by summing up all the contributions:
c˜0(x, t) =
∞∑
k=1
Xk0 (x)G
k(t) c˜1(x, t) =
∞∑
k=1
Xk1 (x)G
k(t) (3.14)
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4 Solution of the full problem
Consider first that, by making explicit ce from eqn. (2.10), cb from eqn. (2.13), and from initial conditions
(2.15), we have
ce(x, t) = exp(−β0t) + δ0
t∫
0
c0(x, τ) exp[β0(τ − t)]dτ (4.1)
cb(x, t) = β1
t∫
0
c1(x, τ) exp[δ1(τ − t)]dτ (4.2)
The eqns. (4.1)–(4.2) mean that ce (resp. cb) are computed in terms of c0 (resp. c1) and the latter are
expressed in the space spanned by Xk
0
(resp. Xk
1
) (see eqn. (3.6)), with the set of eigenvalues and eqn.
(3.10) unchanged, similarly to eqn. (3.14), as:
c0(x, t) =
∞∑
k=1
Xk0 (x)U
k(t) c1(x, t) =
∞∑
k=1
Xk1 (x)U
k(t) (4.3)
where the time functions Uk(t) have to be computed for the complete system (2.10)–(2.13). Replacing
(4.3), eqns. (4.1)-(4.2) are written as:
ce(x, t) = exp(−β0t) + δ0
∞∑
k=1
Xk0 (x)H
k
0 (t) cb(x, t) = β1
∞∑
k=1
Xk1 (x)H
k
1 (t) (4.4)
with
Hk0 (t) =
t∫
0
Uk(τ) exp[β0(τ − t)]dτ H
k
1 (t) =
t∫
0
Uk(τ) exp[δ1(τ − t)]dτ (4.5)
By inserting (4.3)–(4.4) into eqn. (2.11), multiplying by Xp
0
, we get:
∞∑
k=1
Xk0X
p
0
dUk
dt
= −γ
∞∑
k=1
Xk0X
p
0
(λk0)
2Uk − δ0
∞∑
k=1
Xk0X
p
0
Uk
+ β0 exp(−β0t)X
p
0
+ β0δ0
∞∑
k=1
Xk0X
p
0
Hk0 (4.6)
Similarly, multiplying eqn. (2.12) by Xp
1
, we have:
∞∑
k=1
Xk1X
p
1
dUk
dt
= −
∞∑
k=1
Xk1X
p
1
(λk1)
2Uk − β1
∞∑
k=1
Xk1X
p
1
Uk + β1δ1
∞∑
k=1
Xk1X
p
1
Hk1 (4.7)
Integrating the previous eqns over the corresponding layers and summing up, we get:
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∞∑
k=1
dUk
dt

 0∫
−l0
Xk0X
p
0
dx+
1∫
0
Xk1X
p
1
dx

 = − ∞∑
k=1
Uk

γ(λk0)2
0∫
−l0
Xk0X
p
0
dx+ (λk1)
2
1∫
0
Xk1X
p
1
dx


− δ0
∞∑
k=1
Uk
0∫
−l0
Xk0X
p
0
dx− β1
∞∑
k=1
Uk
1∫
0
Xk1X
p
1
dx
+ β0 exp(−β0t)
0∫
−l0
Xp
0
dx+ β0δ0
∞∑
k=1
Hk0
0∫
−l0
Xk0X
p
0
dx+ β1δ1
∞∑
k=1
Hk1
1∫
0
Xk1X
p
1
dx (4.8)
We now pose:
θp
0
=
0∫
−l0
Xp
0
(x)dx = −
bp
0
λp
0
(4.9)
αkp
0
=
0∫
−l0
Xp
0
(x)Xk0 (x)dx α
kp
1
=
1∫
0
Xp
1
(x)Xk1 (x)dx (4.10)
Note that the space integrated constants θp
0
and αkp
0
are the same as those computed in Ref. [17], and,
from the orthogonality condition (3.12), they satisfy:
αkp
0
+ αkp
1
=
{
0 for k 6= p
Nk for k = p
(4.11)
By means of eqn. (3.10), the manipulation of eqn. (4.8) yields:
dUp
dt
+ ωpUp =
1
Np
(
β0 exp(−β0t)θ
p
0
+ β0δ0
∞∑
k=1
Hk0α
kp
0
+ β1δ1
∞∑
k=1
Hk1α
kp
1
)
(4.12)
From eqn (4.5), Hp
0
(t) and Hp
1
(t) can be computed via the Leibnitz rule as:
dHp
0
dt
+ β0H
p
0
= Up
dHp
1
dt
+ δ1H
p
1
= Up
(4.13)
The system of the three ODE’s (4.12)–(4.13), with homogeneous initial conditions:
Up(0) = Hp
0
(0) = Hp
1
(0) = 0 (4.14)
is solved numerically with an explicit Runge-Kutta type solver with an adaptive time step. The obtained
functions Up, Hp
0
and Hp
1
allow the computation of all concentrations in eqns. (4.3)–(4.4).
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From the analytical form of the solution given by eqns. (4.4) the drug masses are easily computed as
integrals of the concentrations over the correspondent layer:
Mj(t) =
∫
cj(x, t)dx j = e, 0, 1, b (4.15)
Furthermore, the fraction of drug mass retained in each layer and phase is computed as:
µj(t) =
Mj(t)
Me(0)
j = e, 0, 1, b (4.16)
These are useful indicators of the drug released, diffused and absorbed during time.
5 Numerical simulations and results
A common difficulty in simulating physiological processes is the identification of reliable estimates of the
model parameters. Experiments of TDD are impossible or prohibitively expensive in vivo and the only
available source are lacking and incomplete data from literature. The physical problem depends on a large
number of parameters, each of them may vary in a finite range, with a variety of combinations and limiting
cases. The model constants cannot be chosen independently from each other and there is a compatibility
condition among them. In this paper, for simplicity, the following physical parameters are kept fixed for
simulations in TDD [4, 11, 20, 21]:
D0 = 5 · 10
−7cm2/s D1 = 7 · 10
−8cm2/s P = 10−6cm/s Kcl = 3 · 10
−3cm/s (5.1)
and the binding/unbinding parameters are varied to study the effect and to quantify the sensitivity of the
delivery system, with the condition that the characteristic reaction times are smaller than the diffusion times,
i.e.: β0 >
D0
l2
0
and β1 >
D1
l2
1
.
The thickness of the vehicle is set as l0 = 40µm, whereas the limit of the skin layer (l1) is estimated by
the following considerations. Strictly speaking, in a diffusion-reaction problem the concentration vanishes
asymptotically at infinite distance. However, for computational purposes, the concentration is damped out
(within a given tolerance) over a finite distance at a given time. Such a length (named penetration distance,
see [16]) critically depends on the diffusive properties of the two-layered medium and, in particular, is
related to the ratio D0
D1
. In our case, l1 falls beyond the stratum corneum thickness, say l1 = 0.1cm.
All the series appearing in the solution (4.4) and following, have been truncated at a number of 40 terms.
The concentration profiles are almost flat in the vehicle, because of its small size, are discontinuous at
the interface, and have a space decreasing behavior at any time in the skin layer, damping out within the
penetration distance at all times (fig. 4). In the skin, a fast phase exchange of drug occurs at early times,
more evident in regions close to the interface x = 0, and continues at later times (fig. 5). The mass Me
is decreasing in the vehicle, and M0 (resp. M1,Mb), is first increasing up to some upper bound M∗0 (resp.
M∗
1
,M∗b ) (at a time t∗0 (resp. t∗1, t∗b ), with t∗0 < t∗1 < t∗b) and then decaying asymptotically with time (fig. 6).
The effect of binding/unbinding is studied by varying systematically the values of the on-off reaction
rates β0, β1, δ0, δ1 over an extended range (this is made feasible by setting the other parameters as in eqn.
(5.1)). One parameter is changed at a time, letting the others fixed. The occurrence and the magnitude of
the drug peak as well as the time scale of the absorption process result to be very sensitive to the mutual size
of reaction parameters, combined with those of diffusive coefficients. In tables 1-4 these values are reported
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for a number of cases.
Effect of β0 and δ0 (tables 1 and 2).
Small values of β0 make the dissolution process slower. In the limit β0 → 0 all drug tends to remain in the
phase ce and it is hardly released and absorbed. For β0 large, the phenomenon is characterized by marked
peaks at early instants. On the other hand, for a fixed β0, the TDD can be greatly influenced by the possible
drug re-association. For a large δ0 the release is slowed down and the drug levels appear to be more uniform,
with lower peak values.
Effect of β1 and δ1 (tables 3 and 4).
In the second layer, the variation of β1 and δ1 influences only the mass M1 and especially Mb, letting the
dynamics of ce and c0 unchanged. A small β1 is responsible for a raise of M1, leaving Mb small. For a β1
sufficiently large (in our simulations ≈ 2 · 10−4s−1) bound drug tends to accumulate at a much greater rate
than it can be transferred from the contiguous layer and the process cannot be sustained by this value. For
small values of δ1 the replenishment of the layer is much faster. In the limit δ1 → 0, M1 vanishes after a
short transient and Mb reaches a steady value.
These outcomes provide valuable indicators to assess whether drug reaches a target tissue, and to opti-
mize the dose capacity in the vehicle. It appears that the relative size of the binding/unbinding parameters
affects the drug transfer processes, thus influencing the mechanism of the whole dynamics. For example,
tables 1-4 show which set of parameters guarantees a more prolonged and uniform release and what other
values are responsible for a localized peaked distribution followed by a faster decay. Thus, the benefit of
reaching the desired delivery rate is obtained with a proper choice of the physico-chemical-geometrical pa-
rameters. The resistance of skin to diffusion has to be reduced in order to allow drug molecules to penetrate
and maintain therapeutic levels for an extended period of time. Increasing skin permeability is a prerequi-
site for successful delivery of new macromolecular drugs and improved delivery of conventional drugs. The
present TDD model constitutes a simple tool that can help in designing and in manufacturing new vehicle
platforms that guarantee the optimal release for an extended period of time.
6 Conclusions
Currently TDD is one of the most promising method for drug administration and an increasing number of
drugs are being added to the list of therapeutic agents that can be delivered topically or systemically through
the skin. A deeper understanding of drug release is necessary for a rational design of TDD system to
optimize therapeutic efficacy and minimize local toxicity. It is important to find a delicate balance between
achieving a highly effective result without compromising the safety of the patient. One of the approaches
to evaluate the characteristics of drug elution from the transdermal patch into the skin and to optimize the
physico-chemical parameters is the mathematical modelling and the numerical simulation.
This paper describes the dissolution and the kinetics of a drug in the delivery device together with the
percutaneous absorption in the skin, as a unique system. This is accomplished by developing a concentration
closed-form solution of a two-phase two-layer model. The analytical approach is useful for experimental
design and clinical application, providing the basis for the optimization of parameters. It helps in identify
and quantify, among the others, the relevant concurrent effects in TDD. The approach captures the essential
physics of drug release and dynamics of the percutaneous absorption. The methodology is equally applicable
to other delivery systems, such as the drug-eluting stent.
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Figure 1: The transdermal patch, a typical vehicle in transdermal drug delivery.
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Figure 2: Cross-section of the vehicle and the skin layers, geometrical configuration and reference system
in TDD. Due to an initial difference of free drug concentrations c0 and c1, a mass flux is established at the
interface and drug diffuses through the skin. At a distance x = l1 the skin-receptor (capillary bed) is present
where all drug is assumed to be absorbed. Figure not to scale.
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free drug di usion
vehicle
Figure 3: A diagram sketching the cascade mechanism of drug delivery and percutaneous absorption in the
vehicle-skin coupled system. A unbinding (resp. binding) reaction occurs in the vehicle (resp. in the skin)
(blue arrows). In both layers, reverse reactions (red arrows) are present in a dynamic equilibrium. Drug
diffusion occurs only in the free phases c0 and c1.
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Figure 4: Concentration profiles in the vehicle (ce and c0 above) and in the skin (c1 and cb below) for the
following dimensional binding/unbinding parameters (s−1): β0 = 10−4, β1 = 1.5 · 10−4, δ0 = 10−4, δ1 =
10−4, at three times (note the different scale of concentrations between the two layers).
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Figure 5: Difference between bound and free concentrations ce− c0 (top) and cb− c1 (bottom) as a function
of time for the same binding-unbinding parameters of fig. 4. In the vehicle a fast decaying phase transfer
is evidenced. Due to its thin size, this phase transition ce → c0 occurs at the same manner at any location,
whereas in the skin it is shown the larger amount of drug phase change at locations near the interface x = 0.
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Figure 6: Time histories of the drug mass in the vehicle (Me and M0) and in the skin (M1 and Mb) for the
same binding-unbinding parameters of fig. 4. Only Me exhibits an exponential decay, whereas M0,M1 and
Mb increase at initial times, reach a peak M∗ at time t∗, and then damp to zero at a given rate.
18
Table 1: Percentage of the two drug mass phases retained in each layer at different times for dimensional
bindind/unbinding parameters (s−1): β1 = 10−4, δ0 = 10−4, δ1 = 10−4 and varying β0 (cfr. eqn. (4.16)).
In the last row of each block the quantity t∗\M∗ refers to the maximum values of M∗ and the correspondent
times t∗ where they are attained.
β0 (s
−1) t(−) t(d : h : m) µe(%) µ0(%) µ1(%) µb(%)
10−6
0.01 ≃ 24m 99 0.1 0.01 < 0.01
0.05 ≃ 2h 99 0.2 0.2 0.05
0.5 ≃ 19h : 50m 95 0.4 1.8 1.6
5 ≃ 8d : 6h : 24m 68 0.3 2.6 2.6
t∗\M∗ 1.32\1.7 · 10−4 2.06\1.2 · 10−3 2.13\1.2 · 10−3
10−4
0.01 ≃ 24m 87 10 1.8 0.09
0.05 ≃ 2h 57 19 18 4.7
0.5 ≃ 19h : 50m 3.9 3.0 34 36
5 ≃ 8d : 6h : 24m 0.01 0.01 0.2 0.2
t∗\M∗ 0.04\8 · 10−3 0.26\0.015 0.36\0.015
10−2
0.01 ≃ 24m 0.75 73 23 1.6
0.05 ≃ 2h 0.2 25 53 20
0.5 ≃ 19h : 50m 0.02 2.2 32 35
5 ≃ 8d : 6h : 24m < 0.01 0.01 0.2 0.2
t∗\M∗ 0.002\0.036 0.06\0.021 0.2\0.018
Table 2: As in table 1, for β0 = 10−4, β1 = 10−4, δ1 = 10−4 (s−1) and varying δ0 (cfr. with second case of
table 1).
δ0 (s
−1) t(−) t(d : h : m) µe(%) µ0(%) µ1(%) µb(%)
10−8
0.01 ≃ 24m 86 11 1.9 0.09
0.05 ≃ 2h 48 24 21 5.4
0.5 ≃ 19h : 50m 0.07 2.5 35 37
5 4d:17h < 0.01 0.01 0.2 0.2
t∗\M∗ 0.05\9.8 · 10−3 0.19\0.017 0.31\0.016
10−2
0.01 ≃ 24m 98 0.9 0.2 0.01
0.05 ≃ 2h 97 0.9 1.0 0.3
0.5 ≃ 19h : 50m 88 0.8 4.5 4.1
5 ≃ 8d : 6h : 24m 47 0.4 3.6 3.6
t∗\M∗ 0.006\3.8 · 10−4 1.30\2.5 · 10−3 1.37\2.5 · 10−3
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Table 3: As in table 1, for β0 = 10−4, δ0 = 10−4, δ1 = 10−4 (s−1) and varying β1 (cfr. with second case of
table 1).
β1 (s
−1) t(−) t(d : h : m) µe(%) µ0(%) µ1(%) µb(%)
10−6
0.01 ≃ 24m 87 10 1.9 < 0.01
0.05 ≃ 2h 57 20 22 0.05
0.5 ≃ 19h : 50m 4.9 3.9 48 0.5
5 ≃ 8d : 6h : 24m < 0.01 < 0.01 < 0.01 < 0.01
t∗\M∗ 0.04\8 · 10−3 0.24\0.026 0.33\2.4 · 10−4
2 · 10−4
0.01 ≃ 24m 87 10 1.7 0.18
0.05 ≃ 2h 57 19 14 8.2
0.5 ≃ 19h : 50m 3.3 2.5 26 55
5 ≃ 8d : 6h : 24m 0.06 0.06 0.9 2.0
t∗\M∗ 0.04\8 · 10−3 0.30\0.011 0.40\0.022
Table 4: As in table 1, for β0 = 10−4, δ0 = 10−4, β1 = 10−4 (s−1) and varying δ1 (cfr. with second case of
table 1).
δ1 (s
−1) t(−) t(d : h : m) µe(%) µ0(%) µ1(%) µb(%)
10−8
0.01 ≃ 24m 87 10 1.8 0.09
0.05 ≃ 2h 57 19 17 5.6
0.5 ≃ 19h : 50m 1.7 0.8 2.4 90
5 ≃ 8d : 6h : 24m < 0.01 < 0.01 < 0.01 95
t∗\M∗ 0.04\8 · 10−3 0.11\0.01 1.62\0.03
10−2
0.01 ≃ 24m 87 10 1.9 0.01
0.05 ≃ 2h 57 20 22 0.2
0.5 ≃ 19h : 50m 4.9 3.9 48 0.4
5 ≃ 8d : 6h : 24m < 0.01 < 0.01 < 0.01 < 0.01
t∗\M∗ 0.04\8 · 10−3 0.24\0.026 0.24\2.6 · 10−4
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